Status:
UNKNOWN
Subjects Through the Application of the Mindera Kit Part 2
Lead Sponsor:
Mindera Health
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
A 16 week study to examine if baseline or on-therapy transcriptomics can be used to help predict selection of medications and provide new therapeutic targets for drug development in psoriasis subjects...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Subject must have the ability to understand and sign written informed consent.
- Subject must be an adult male or female adult who is ≥ 18 years of age at the time of screening.
- Subject must be diagnosed with psoriasis by either a dermatologist or a rheumatologist, with the affected area of ≥ 2 centimeters in diameter.
- Subjects must be treated with anti-TNF-α (or biosimilar) therapy once enrolled in the study.A two-week period is required to washout of the previous biologic when switching therapies.
- Exclusion Criteria
- Subject is unable or unwilling to give written informed consent and/or to comply with study procedures.
- Subject has had usage of topical psoriasis treatments on study lesion within 2 weeks prior to baseline studyvisit and unwilling to washout.
- Subjects currently treated with Hydroxychloroquine (Plaquenil), unless otherwise approved by Sponsor
Exclusion
Key Trial Info
Start Date :
August 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04904315
Start Date
August 1 2021
End Date
May 30 2022
Last Update
May 27 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.